Less Ads, More Data, More Tools Register for FREE

Pin to quick picksE2V.L Regulatory News (E2V)

  • There is currently no data for E2V

Interim Management Statement

19 Jul 2010 07:00

RNS Number : 5178P
e2v technologies PLC
19 July 2010
Β 

ο»Ώ

Monday 19 July, 2010

Β 

e2v technologies plc

Β 

Interim Management Statement

Β 

e2v technologies, the specialist developer and manufacturer of high technology components and sub-systems, is providing this Interim Management Statement coveringΒ the periodΒ from 1 April 2010 to 16 July 2010.

Β 

Summary

Β 

The Group's trading since the 31 March 2010 year end has been significantly ahead of the comparable period in 2009/10. Current demand levels and order book strength, along with cost control, indicate that this year's trading performance has the potential to be towards the upper end ofΒ management's range of expectations.

Β 

Electron devices and sub-systems division

Β 

Medical and science is ahead of the comparable period, with radiotherapy experiencing continuing strong OEM demand. Commercial and industrial has experienced further growth, reflecting a recovery in the underlying markets. The defence sector is up on the prior period, mainly reflecting short term activity to support the transfer of the operations from the Lincoln site to the Chelmsford site, though order placement continues to be weak.

Β 

Imaging division

Β 

Commercial and industrial experienced continuing strong demand for machine vision. Medical and science showed growth in scientific imaging, while dental is down from the same period last year. Sales in the space sector were lower due to some technical and order phasing issues.

Β 

Specialist semiconductors divisionΒ 

Β 

Aerospace and defence experienced continuing growth due to test and assembly services. Commercial and industrial is up compared to last year due to some recovery of overdue orders.

Β 

Order book

Β 

The order book for delivery over the next 12 months as at 30 June 2010 was Β£146m (30 June 2009: Β£127m). The increase of Β£19m reflects improved underlying demand from certain sectors as well as 'one off' orders of Β£15m associated with the restructuring. Although overdue orders have reduced, these are still at an unusually high level and should return to normalised levels during the third quarter of this financial year.

Β 

Β 

Restructuring programme

Β 

The restructuring programme continues to progress well and is marginally ahead of plan. Whilst there remains ongoing risk pending the completion of the implementation phase, management currently anticipate that the programme will be delivered in line with plan.

Β 

R&D spend

Β 

During the course of the strategic review, R&D spend has continued to be restrained.

Β 

Financial Position

Β 

Net borrowings (see note 4) at 30 June 2010 increased, as anticipated, by Β£5m from 31 March 2010 to Β£50m. This reflects the expected working capital changes and operating cash flow being used to fund reorganisation costs.

Β 

Strategy Briefing

Β 

The Group is executing a three step recovery programme: re-financing the Group; ongoing implementation of the accelerated business improvement programme; and returning the Group to organic growth. A strategy briefing is taking place on 26 July 2010 to analysts and institutional investors, to communicate the outcome of our strategic review and the resulting implementation plans.

Β 

Β 

Enquiries:Β 

e2v technologies plc

Tel: +44 (0)1245 493 493

Keith Attwood/Charles Hindson

www.e2v.com

Financial Dynamics

Tel: +44 (0)20 7831 3113

Jon Simmons/Sophie McMillan

Β 

Β 

Notes for editors

Β 

1. The next timetabled trading update is the release of the Period End Update on Monday 11th October 2010 followed by the release of the Group's interim results for the six months ending 30 September 2010 on Monday 15th November 2010.

2. Statements made in this announcement that look forward in time or that express management's beliefs, expectations or estimates regarding future occurrences are "forward-looking statements" within the meaning of the United States federal securities laws. These forward-looking statements reflect the Group's current expectations concerning future events and actual results may differ materially from current expectations or historical results.

3. All financial information included in this release is sourced from management accounts.

4. Net borrowings exclude capitalised borrowing costs.

Β 

e2v's objective is to be a global leader in the design and supply of specialised components and sub-systems that enable the world's leading systems companies to deliver innovative solutions for medical & science, aerospace & defence, and commercial & industrial markets.

Β 

e2v is organised into three divisions:

Electron devices and sub-systems division

High performance microwave electron devices and subsystems for applications including defence electronic countermeasures, radiotherapy cancer treatment, radar systems, microwave radar, safety and arming devices, industrial heating, satellite communications amplifiers and digital television transmitters.

Imaging Division

Advanced CCD and CMOS imaging sensors and cameras for applications including space, science and life science imaging, industrial process control, intra-oral and panoramic dental X-ray systems, military surveillance and automotive imaging.

Specialist semiconductors division.

Specialist SemiconductorsΒ -Β including logic, memory and microprocessors forΒ high reliability microprocessor and MRAM requirements, in partnership with Freescale SemiconductorΒ andΒ Everspin,Β mission-critical avionics and defence programs requiring high reliability integrated circuits, high speed data convertersΒ and sensor data acquisitionΒ utilising mixed signal application specific devices.

The Company is headquartered in the United Kingdom and has six production facilities across Europe and North America. e2v also operates a global network of sales and technical support offices, supported by local distributors and resellers.

Β 

Further information is available from www.e2v.com

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
IMSGGURGMUPUGBR
Date   Source Headline
3rd Jan 20144:37 pmRNSHolding(s) in Company
5th Dec 201311:42 amRNSAdditional Listing
27th Nov 201311:35 amRNSGeneral Meeting
19th Nov 20134:25 pmRNSNOTIFICATION OF MAJOR INTEREST IN SHARES
14th Nov 20133:27 pmRNSNotification of Major Interest in Shares
14th Nov 201312:49 pmRNSNotice of General Meeting
6th Nov 20134:57 pmRNSTransaction in Own Shares
4th Nov 201311:44 amRNSDirector/PDMR Shareholding
4th Nov 20137:00 amRNSHalf-year results for six months to 30 Sept 2013
18th Oct 20137:00 amRNSAppointment of Chief Executive
15th Oct 20137:00 amRNSPeriod end update
14th Oct 20134:15 pmRNSHolding(s) in Company
1st Oct 20134:51 pmRNSTransaction in Own Shares
27th Sep 20134:18 pmRNSPurchase of Own Shares
23rd Sep 20134:00 pmRNSShare buy-back programme
19th Aug 20132:15 pmRNSTotal Voting Rights
13th Aug 20134:15 pmRNSHolding(s) in Company
13th Aug 20131:30 pmRNSDirector/PDMR Shareholding
23rd Jul 20137:00 amRNSDirector/PDMR Shareholding
19th Jul 20137:00 amRNSAwards under Long Term Incentive Plan
17th Jul 20131:45 pmRNSAnnual General Meeting 2013
17th Jul 20137:00 amRNSDirectorate Change
17th Jul 20137:00 amRNSInterim Management Statement
1st Jul 20134:35 pmRNSHolding(s) in Company
26th Jun 20134:29 pmRNSHolding(s) in Company
26th Jun 201311:11 amRNSHolding(s) in Company
12th Jun 201312:00 pmRNSDirectorate Change
20th May 20132:20 pmRNSDirector/PDMR Shareholding
20th May 20137:00 amRNSResults for the year ended 31 March 2013
25th Apr 20133:58 pmRNSNotification of Major Interest in Shares
22nd Apr 20135:00 pmRNSNotification of Major Interest in Shares
16th Apr 20137:00 amRNSTrading Statement
9th Apr 201310:00 amRNSTotal Voting Rights
18th Mar 20134:00 pmRNSNotification of Major Interest in Shares
18th Mar 20137:00 amRNSe2v wins ?10m ESA space science contract
6th Mar 20133:11 pmRNSHolding(s) in Company
6th Mar 20132:15 pmRNSHolding(s) in Company
5th Mar 20137:00 amRNSContract Renewal
22nd Feb 20132:02 pmRNSNotification of Major Interest in Shares
14th Feb 201311:00 amRNSDirector/PDMR Shareholding
12th Feb 20134:43 pmRNSDirector/PDMR Shareholding
12th Feb 201311:10 amRNSHolding(s) in Company
11th Feb 20134:13 pmRNSTotal Voting Rights
11th Feb 20137:00 amRNSAppointment of Non-Executive Chairman
31st Jan 20137:00 amRNSInterim Management Statement
8th Jan 201311:40 amRNSTotal Voting Rights
7th Jan 20131:59 pmRNSDirector/PDMR Shareholding
7th Dec 20127:00 amRNSContract Renewal
3rd Dec 20127:00 amRNSSale of land
30th Nov 20123:39 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.